Immunoregulation mRNA Products

product-img

Introduction Product List Product FeaturesApplication Q&A

Introduction

The immune system is an important system for the execution of body's immune response and has the role of immune surveillance, defence and regulation. It is mainly composed of immune organs, immune cells and immune active substances. Immunologically active substances are the signalling links of immune system and are mainly involved in the regulation of immune response to maintain the balance and stability of immune system, including membrane molecules (TCR, BCR, CD molecules, adhesion molecules, MHC molecules,etc.) and secretory molecules (lgA, lgD, lgM, etc.). Creative Biolabs offers a range of immunoregulation mRNA products based on IVTScrip™ synthesis platform, which are highly stable and efficiently translated. These mRNA products have been expertly designed with varying lengths and excellent purity, as well as biological activity to support your project in immune mechanism research and drug development related to immune system diseases.

In addition to pre-formulated immunoregulation mRNA products, Creative Biolabs provides a variety of purification options and modification strategies to customize mRNA to customers' experimental needs. Based on the advanced IVTScrip™ synthesis platform, a wide range of mRNA strand lengths and specifications are available for customisation. Here mRNA can be generated at milligram to multigram with lengths ranging from a few hundred nucleotides to greater than 10 kilobases. Given over 10 years experience of our experts in mRNA synthesis and modification, customisation lead time is relatively short and services are competitively priced. If you are interested in our products, please feel free to contact us.

Product List

>>>Can't find what your looking for? Contact us and we will be happy to help.

Product Features

Strict Quality Control Standards
- Multiple quality control standards.
- High stability and batch-to-batch consistency.
- Excellent purity and stability profile.
Efficient and Time-saving
- Pre-designed capping and poly (A) tail modification.
- Shorter turnaround time.

Application

Vaccine Development: One of the most groundbreaking applications of immunoregulation mRNA is in the development of vaccines, particularly for infectious diseases. By encoding antigens specific to pathogens (viruses or bacteria), mRNA vaccines instruct the host cells to produce these antigens, thereby stimulating a protective immune response. This approach was spectacularly demonstrated by the rapid development and deployment of mRNA vaccines against SARS-CoV-2, the virus responsible for COVID-19.
Immune System Modelling: Immunoregulation mRNA is extensively used in experimental models to study the immune system's intricacies. By introducing mRNA encoding specific cytokines or immune modulators, scientists can precisely control the immune environment within a model system, whether in vitro (e.g., cell cultures) or in vivo (e.g., animal models). This enables the detailed investigation of immune responses, including the mechanisms of immune activation, suppression, and the dynamics of immune cell interactions.
Cancer Immunotherapy: In cancer therapy, immunoregulation mRNA is employed to harness the immune system against cancer cells. Therapeutic cancer vaccines based on mRNA are designed to encode tumor-associated antigens, thus priming the immune system to recognize and eliminate cancer cells. Additionally, mRNA encoding immune checkpoint inhibitors can be used to overcome the mechanisms by which tumors evade immune detection, effectively boosting the immune response against the tumor.
Allergy Treatment: Similarly, immunoregulation mRNA can be engineered to express allergen-specific antigens in a controlled manner, aiming to desensitize the immune system and prevent allergic reactions. This approach represents a potential shift in allergy treatment, moving towards more specific and effective therapies compared to traditional methods.
Infectious Disease Therapies: Immunoregulation mRNA has potential in the treatment and prevention of infectious diseases other than COVID-19. Pre-clinical development programs are examining the efficacy of mRNA therapies for diseases such as influenza, Zika, and rabies.

Q&A

Q:1 What are the key considerations for the delivery of immunoregulatory mRNA in vivo?

A: For successful in vivo delivery, considerations include selecting appropriate delivery vehicles like lipid nanoparticles (LNPs) or polymers that can protect mRNA from degradation, targeting specific cell types or tissues, and minimizing off-target effects to ensure safety and efficacy.

Q2: How does mRNA-based immunoregulation compare to traditional protein-based therapies?

A: mRNA-based therapies offer several advantages over protein-based therapies, including the ability to rapidly design and synthesize mRNA for any protein, lower production costs, and the potential for transient expression without integrating into the host genome, reducing long-term safety concerns.

Q3: What is the preferred method for synthesizing immunoregulation mRNA and why?

A: In vitro transcription (IVT) from a DNA template is preferred due to its ability to produce large quantities of mRNA. This method can be easily scaled up and allows for the incorporation of modified nucleotides to enhance stability and translation.

Q4: What methods are used to control the temporal expression of immunoregulation mRNA in vivo?

A: Incorporating inducible promoters that respond to external stimuli (like doxycycline) allows for controlled expression timing. Alternatively, designing mRNA molecules that degrade under specific conditions or after a predetermined time can provide temporal control.

Q5: How to predict the behavior and efficacy of immunoregulation mRNA in different tissues or disease states?

A: Computational models can simulate the kinetics of mRNA uptake, translation, and degradation, as well as predict the immune response based on various parameters. These models help in optimizing mRNA design and delivery strategies before in vivo testing.

Q6: How can the temporal and spatial expression of immunoregulatory mRNA be controlled in vivo to mimic natural immune regulatory processes?

A: The temporal and spatial expression of immunoregulatory mRNA in vivo can be controlled by employing advanced technologies such as CRISPR-Cas9 for gene editing, alongside innovative delivery strategies for the precise localization. This can be further combined with the use of synthetic biology approaches to program the timing and level of mRNA expression, thus mimicking natural immune regulatory processes.

Q7: What specific mRNA modifications can enhance the translation efficiency of immunoregulatory proteins without eliciting an unintended immune response?

A: Specific mRNA modifications such as 5' cap addition, 3' poly-A tail elongation and codon optimization can enhance translation efficiency of immunoregulatory proteins. Chemical modifications like pseudouridine and 5-methylcytidine can prevent unintended immune response by minimizing recognition by innate immune sensors.

Q8: What is the impact of the extracellular microenvironment on the uptake and efficacy of immunoregulatory mRNA, and how can this knowledge be leveraged to improve therapeutic outcomes?

A: The extracellular microenvironment can impact the uptake and efficacy of immunoregulatory mRNA. Factors such as pH, presence of enzymes, and extracellular matrix can affect mRNA delivery. Understanding these factors can help in designing more effective mRNA therapies. For instance, lipid nanoparticles can be engineered to protect mRNA under hostile conditions and ensure efficient delivery.

IVTScrip™ mRNA-Human CD200, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WK0009MR)

Product type mRNA

Transcript CD200

Category (CDS) Immunoregulation

Applications Gene therapy research